Norges Bank’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-451,338
| Closed | -$4.67M | – | 2031 |
|
|
2023
Q2 | $4.67M | Hold |
451,338
| – | – | ﹤0.01% | 1737 |
|
|
2023
Q1 | $4.9M | Sell |
451,338
-94,089
| -17% | -$995K | ﹤0.01% | 1762 |
|
|
2022
Q4 | $6.12M | Hold |
545,427
| – | – | ﹤0.01% | 1720 |
|
|
2022
Q3 | $5.53M | Hold |
545,427
| – | – | ﹤0.01% | 1730 |
|
|
2022
Q2 | $4.94M | Buy |
545,427
+12,333
| +2% | +$114K | ﹤0.01% | 1773 |
|
|
2022
Q1 | $5.1M | Hold |
533,094
| – | – | ﹤0.01% | 1866 |
|
|
2021
Q4 | $5.89M | Buy |
533,094
+290,600
| +120% | +$2.53M | ﹤0.01% | 1892 |
|
|
2021
Q3 | $1.79M | Sell |
242,494
-168,117
| -41% | -$1.88M | ﹤0.01% | 2069 |
|
|
2021
Q2 | $5.96M | Sell |
410,611
-99,400
| -19% | -$1.87M | ﹤0.01% | 1876 |
|
|
2021
Q1 | $10.4M | Sell |
510,011
-147,670
| -22% | -$2.81M | ﹤0.01% | 1780 |
|
|
2020
Q4 | $11.7M | Sell |
657,681
-352,142
| -35% | -$6.32M | ﹤0.01% | 1736 |
|
|
2020
Q3 | $14.9M | Sell |
1,009,823
-247,064
| -20% | -$4.63M | ﹤0.01% | 1589 |
|
|
2020
Q2 | $26.4M | Buy |
1,256,887
+199,374
| +19% | +$5.12M | 0.01% | 1265 |
|
|
2020
Q1 | $24.4M | Sell |
1,057,513
-18,076
| -2% | -$452K | 0.01% | 1112 |
|
|
2019
Q4 | $27.8M | Buy |
1,075,589
+120,000
| +13% | +$2.33M | 0.01% | 1321 |
|
|
2019
Q3 | $18.6M | Buy |
955,589
+27,333
| +3% | +$552K | 0.01% | 1522 |
|
|
2019
Q2 | $15.2M | Buy |
928,256
+52,083
| +6% | +$1.06M | ﹤0.01% | 1641 |
|
|
2019
Q1 | $19.9M | Hold |
876,173
| – | – | 0.01% | 1516 |
|
|
2018
Q4 | $22.4M | Buy |
876,173
+37,425
| +4% | +$1.01M | 0.01% | 1325 |
|
|
2018
Q3 | $27.4M | Buy |
838,748
+39,215
| +5% | +$1.07M | 0.01% | 1329 |
|
|
2018
Q2 | $18.1M | Buy |
799,533
+81,780
| +11% | +$1.94M | 0.01% | 1583 |
|
|
2018
Q1 | $17.4M | Sell |
717,753
-57,044
| -7% | -$1.57M | 0.01% | 1521 |
|
|
2017
Q4 | $21.6M | Sell |
774,797
-28,530
| -4% | -$844K | 0.01% | 1425 |
|
|
2017
Q3 | $27.5M | Hold |
803,327
| – | – | 0.01% | 1223 |
|
|
2017
Q2 | $32M | Hold |
803,327
| – | – | 0.01% | 1066 |
|
|
2017
Q1 | $29.6M | Sell |
803,327
-63,397
| -7% | -$2.03M | 0.01% | 1107 |
|
|
2016
Q4 | $27.6M | Hold |
866,724
| – | – | 0.01% | 1085 |
|
|
2016
Q3 | $30M | Buy |
866,724
+396,118
| +84% | +$11M | 0.01% | 938 |
|
|
2016
Q2 | $10.7M | Buy |
470,606
+128,087
| +37% | +$2.77M | 0.01% | 1572 |
|
|
2016
Q1 | $6.44M | Sell |
342,519
-68,871
| -17% | -$1.13M | ﹤0.01% | 1749 |
|
|
2015
Q4 | $6.74M | Sell |
411,390
-378,205
| -48% | -$6M | ﹤0.01% | 1786 |
|
|
2015
Q3 | $8.68M | Sell |
789,595
-210,661
| -21% | -$2.68M | ﹤0.01% | 1637 |
|
|
2015
Q2 | $13M | Buy |
1,000,256
+89,980
| +10% | +$1.4M | 0.01% | 1460 |
|
|
2015
Q1 | $15.8M | Buy |
910,276
+664,659
| +271% | +$12.2M | 0.01% | 1356 |
|
|
2014
Q4 | $3.67M | Hold |
245,617
| – | – | ﹤0.01% | 1994 |
|
|
2014
Q3 | $5.66M | Sell |
245,617
-245,617
| -50% | -$7.13M | ﹤0.01% | 1875 |
|
|
2014
Q2 | $15.7M | Buy |
+491,234
| New | +$14.8M | ﹤0.01% | 1737 |
|
Other funds holding TBPH
WAM
BG
MAP
ICM
PWAM
NM
Norges Bank's TBPH Position: Q3 2023 in Review
Norges Bank sold out of Theravance Biopharma (TBPH) in Q3 2023, closing a stake of 451,338 shares — an estimated $4.67M sold.
Norges Bank first reported a position in TBPH in Q2 2014 and held it in 37 quarters. The position peaked at $32M in Q2 2017. 115 funds tracked by Wall St. Rank hold TBPH as of Q3 2023.
- Norges Bank reported no remaining Theravance Biopharma position as of Q3 2023 after selling out during the quarter.
- Norges Bank sold 451,338 Theravance Biopharma shares in Q3 2023, an estimated $4.67M.
- Norges Bank first reported a position in Theravance Biopharma in Q2 2014 and held it in 37 quarters.
- Norges Bank's Theravance Biopharma position peaked at $32M in Q2 2017.
- 115 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2023.
Based on Norges Bank's 13F filing for Q3 2023, filed 13 Nov 2023.